SCHEMBL18940291

SCHEMBL18940291

Cc1nc(N2CCC(CNS(C)(=O)=O)C2)ccc1Br

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMO Q99835 4/20 0.42
IRAK1 P51617 1/20 0.42
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41
AURKA O14965 2/20 0.37
AURKB Q96GD4 2/20 0.37
F10 P00742 3/20 0.37
PTGER4 P35408 1/20 0.36
NPY5R Q15761 2/20 0.35
ADRA2A P08913 1/20 0.35
ENPP1 P22413 1/20 0.35
PIK3CD O00329 2/20 0.35
PIK3R1 P27986 2/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CB P42338 2/20 0.35
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18940311 0.82 PTGER4 (0.43) JAK2JAK1TYK2JAK3PTGER4
SCHEMBL16829647 0.79 SMO (0.52) SMOJAK2JAK1TYK2JAK3
SCHEMBL16829641 0.79 JAK2 (0.43) JAK2JAK1TYK2JAK3PTGER4
SCHEMBL23927779 0.76 CKS1B (0.52) IRAK1
SCHEMBL15464257 0.76 SMO (0.38) SMOJAK2JAK1TYK2JAK3
SCHEMBL18940284 0.76 CKS1B (0.52) IRAK1
SCHEMBL30066438 0.73 PDE10A (0.43) JAK2JAK1TYK2JAK3PTGER4
SCHEMBL24669937 0.73 PDE10A (0.43) JAK2JAK1TYK2JAK3PTGER4
SCHEMBL10324203 0.72 HSD11B1 (0.46) JAK2JAK1TYK2JAK3HSD11B1
SCHEMBL15515890 0.72 METAP2 (0.46) JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3974413-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2022-03-30 EP disclosed
EP-3082786-B1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME (US) 2021-10-27 EP disclosed
US-9834563-B2 Antidiabetic substituted heteroaryl compounds MERCK SHARP & DOHME CORP. (US) 2017-12-05 US disclosed
US-20170166578-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME LLC 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166578-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS GPR119, GPR65, GPR55 SMO 727/4885IRAK1 726/4885JAK2 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.